Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 1, 2012, Pages 84-91

  Jeon, Hyewon ^a   Lim, Kyoung Soo ^a   Shin, Kwang Hee ^a   Kim, Jaewoo ^a,b   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

drug drug interaction; fimasartan; hydrochlorothiazide; pharmacokinetics

Indexed keywords

FIMASARTAN; HYDROCHLOROTHIAZIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG TOLERABILITY; DRUG URINE LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; OPEN STUDY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINE VOLUME;

ADMINISTRATION, ORAL; ADULT; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; MALE; MIDDLE AGED; PYRIMIDINES; RENIN; TANDEM MASS SPECTROMETRY; TETRAZOLES; YOUNG ADULT;

EID: 84855352241     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318237389e     Document Type: Article

References (33)

1. Fimasartan [package insert]. Seoul, South Korea: Boryung Pharmaceutical Co. Ltd.; 2010.
2. Miura S, Karnik SS, Saku K. Review: Angiotensin II type 1 receptor blockers: Class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst. 2011;12:1-7.
3. Bohler S, Pittrow D, Bramlage P, et al. Drug interactions with angiotensin receptor blockers. Expert Opin Drug Saf. 2005;4:7-18.
4. Redon J, Fabia MJ. Efficacy in angiotensin receptor blockade: A comparative review of data with olmesartan. J Renin Angiotensin Aldosterone Syst. 2009;10:147-156.
5. Lane A, Engmann E, Bryson S, et al. Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharmacol Ther. 2005;77:P59-P59.
6. Lane A, Kleinermanns D, Bryson S, et al. Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharmacol Ther. 2005;77:P58-P58.
7. Chi YH, Lee H, Paik SH, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of fimasartan, a novel angiotensin II receptor antagonist, in healthy subjects. Am J Cardiovasc Drugs. In Press.
8. Yi S, Kim TE, Yoon SH, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol. 2011;57:682-689.
9. Shin KH, Kim TE, Kim SE, et al. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol. 2011 July 14 [Epub ahead of print].
10. Jackson Edwin K. Diuretics. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, New York, McGraw-Hill, p. 737. Available at: http://www.accessmedicine. com/content.aspx?aID=943427.
11. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289: 2560-2572. (Pubitemid 37430158)
12. Shimosawa T, Gohchi K, Yatomi Y, et al. Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: Losartan/hydrochlorothiazide vs. candesartan/amlodipine. Hypertens Res. 2007;30:831-837. (Pubitemid 47578245)
13. Meyer MC, Whyatt PL. Hydrochlorothiazide. J Am Pharm Assoc. 1976; 16:47-50.
14. Maillard MP, Wurzner G, Nussberger J, et al. Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing. Clin Pharmacol Ther. 2002;71:68-76. (Pubitemid 34124040)
15. Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens. 2007;20:907-916. (Pubitemid 47176356)
16. Young CL, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol. 2000;40(pt 1):1323-1330.
17. Palatini P. Combination therapy in the management of hypertension: Focus on angiotensin receptor blockers combined with diuretics. J Clin Hypertens (Greenwich). 2005;7:96-101.
18. O'Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821-848. (Pubitemid 36677141)
19. Ruilope LM, Simpson RL, Toh J, et al. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press. 1996;5:32-40. (Pubitemid 26086344)
20. Lacourciere Y, Poirier L, Lefebvre J, et al. Increasing the doses of both diuretics and angiotensin receptor blockers is beneficial in subjects with uncontrolled systolic hypertension. Can J Cardiol. 2010;26:313-319.
21. McCrea JB, Lo MW, Tomasko L, et al. Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J Clin Pharmacol. 1995;35:1200-1206. (Pubitemid 26020043)
22. Kreutz R, Bolbrinker J, Huber M. Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Clin Drug Investig. 2006;26:29-34. (Pubitemid 43098406)
23. Hartman D, Sagnella GA, Chesters CA, et al. Direct renin assay and plasma renin activity assay compared. Clin Chem. 2004;50: 2159-2161. (Pubitemid 39425859)
24. Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol. 1999;128:523-529. (Pubitemid 29504739)
25. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77. (Pubitemid 32050438)
26. Stangier J, Su CA, Fraunhofer A, et al. Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40(pt 1):1338-1346.
27. Hollenberg NK. Renal implications of angiotensin receptor blockers. Am J Hypertens. 2001;14(pt 2):237S-241S. (Pubitemid 32607303)
28. Lansang MC, Osei SY, Price DA, et al. Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan. Hypertension. 2000;36:834-838.
29. Vallon V, Rieg T, Ahn SY, et al. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008;294: F867-F873.
30. Mazzolai L, Maillard M, Rossat J, et al. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension. 1999;33:850-855. (Pubitemid 29140445)
31. Azizi M, Chatellier G, Guyene TT, et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995;92:825-834.
32. Azizi M, Bissery A, Lamarre-Cliche M, et al. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension. 2004;43:785-790. (Pubitemid 38405588)
33. Griffing GT, Sindler BH, Aurecchia SA, et al. The effects of hydrochlorothiazide on the renin-aldosterone system. Metabolism. 1983;32: 197-201. (Pubitemid 13194657)